# Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects

> **NCT02502812** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** Clop F1
- **DRUG:** Clop F2
- **DRUG:** Innovator

## Key facts

- **NCT ID:** NCT02502812
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-04
- **Primary completion:** 2015-09-24
- **Final completion:** 2015-09-24
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502812, "Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02502812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*